DOCUMENTS

98

 

NOTICES

156

 

 

MOTS CLES

Ankylosing spondylitis Bacterial rhinosinusitis Network meta-analysis Apremilast ASDAS Spondyloarthritis Anxiety Quality of life Drug reaction Meta-Analysis Aging Placebo Ethics Pharmaco-Épidémiologie Systematic review Pregnancy Beta-lactam antibiotics Cancer Biosimilar Pharmaceuticals Addiction ArtThese Anti-HCV Direct Acting Antivirals DAA Alitretinoin Amyloidosis Antimicrobials Anti-TNF Antibiotics Biologic therapy Immune checkpoint inhibitors Abus d'antibiotiques Antimicrobiens Sacroiliitis Angiotensin-converting enzyme inhibitors Biological Therapy Biologics Acute Myeloid Leukaemia AML Infliximab Azathioprine Ustekinumab Pharmacovigilance Spondylitis BTK protein Auto-immune hepatitis Adolescent Antimicrobial Stewardship Angiotensin receptor blockers Antibiotic misuse Anti-Bacterial Agents Atrial fibrillation Drug survival Biomarkers Primary adrenal insufficiency Glucocorticoids Ankylosing Anxiété Alcohol Antimicrobial resistance Management Epidemiology Cardiotoxicity Psoriatic arthritis Autoimmune diseases Atopic dermatitis Etanercept Treatment Albinism Sipuleucel-T Endocrine toxicity Immunotherapy Arrhythmia Stability Autoimmunity Access to care Apre-milast Psoriasis Intensive care Arthritis Antibiotic resistance Cardiomyopathy Axial spondyloarthritis Bacterial Adalimumab Biological therapy Vigibase® Adverse side effects Dermatology Burden Auto-Diagnostic COVID-19 Biologic drug Biologic Méta-Analyse Cardio-oncology Biomédicaments Accelerometer Prostate cancer Graft-versus-host disease Anticancer drugs Pharmacoepidemiology Immune-related adverse events

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS